Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Date:1/25/2008

risk of heart attack and stroke. The niacin receptor, a G protein-coupled receptor, or GPCR, is believed to have potential in regulating plasma lipid profiles, including HDL.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic and other potential of niacin receptor agonists; the results of the Phase 1 clinical trial of a second generation niacin receptor agonist; the continuation and progress of the collaboration between Merck and Arena and the activities and program thereunder; the niacin receptor's potential in regulating plasma lipid profiles; the potential of drugs that influence HDL cholesterol to provide clinical benefits to patients; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... April 30, 2015  The Paul G. Allen Family ... (ADI) grants to six groups of researchers with projects ... roadblocks in neuroscience: growing mature human brain cells in ... of $7.5 million over three years.  ... research is especially significant because the field of neuronal ...
(Date:4/30/2015)... 30, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... global contract R&D services provider, today announced that its ... letter, dated April 29, 2015, from a consortium (the ... "Chairman"), founder, chairman and chief executive officer of the ... proposes a transaction (the "Transaction") involving the acquisition of ...
(Date:4/30/2015)... 2015 Clinovo Staffing Solutions ... Conference held in Orlando, FL on May 17-20th, ... with Leslie Kolman, Manager of Staffing Solutions, will present ... at Booth #17. , “We are excited to ... year”, Says Trisha Heredia, Senior Director of Staffing Solutions ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC ... announced today that Gary Rabin, the company,s interim chairman ... BIO-Europe Spring 2011 Conference, March 14-16, at the Milano ... scheduled for Wednesday, March 16, at 10:15 a.m. CET, ...
... --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI ... medicine, modernized traditional Chinese medicine, branded generics and other ... Annual OC Growth Stock Conference from March 13 - ... California. Dr. James Jiayuan Tong, Chief Financial ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ; ... products, today announced its financial results for the fourth quarter ... "2010 was an exciting year for the Company, but we ... to sales growth of XIAFLEX® in the U.S., as well ...
Cached Biology Technology:ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... This press relase is available in Spanish ... coloration of pickles, skin during fermentation may actually help ... a U.S. Department of Agriculture (USDA) study. ... when combined with tartrazine, a yellow food-coloring agent used ...
... of a portion of the tuberculosis genome that responds to ... Tiwari to zero in on a network of genes that ... cause tuberculosis (TB), Mycobacterium tuberculosis, can transition into a dormant ... system. A new report from Igoshin and Tiwari in this ...
... 2010 Science in Society Journalism Awards, sponsored by the National ... In the Book category, Susan Cohen and Christine Cosgrove for ... Medical Industry,s Quest to Manipulate Height" (Tarcher/Penguin). In ... Associated Press and the New York Times. Martha Mendoza and ...
Cached Biology News:Pickle spoilage bacteria may help environment 2Study finds possible 'persistence' switch for tuberculosis 2Study finds possible 'persistence' switch for tuberculosis 3Science in Society Journalism Award winners announced 2Science in Society Journalism Award winners announced 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
... Star strains are high-performance ... improved protein yield in ... (Figure 1). Because the ... mRNA more rapidly than ...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: